A rare autoimmune disorder was behind Mr Hazwady Nazran's paranoid delusions, memory loss and seizures. Read more at ...

Hazwady Nazran, now 38, was hospitalised with mysterious and terrifying symptoms such as violent episodes, paranoid delusions, confusion, memory loss and seizures. If his wife, Dr Miria Hastuti ...

AV-101 is a small molecule commercialized by VistaGen Therapeutics, with a leading Phase I program in Drug-Induced Dyskinesia.

The drug candidate is administered as intravenous and subcutaneous infusion. MIJ-821 acts by targeting NR2B. It is developed based on subtype-selective NMDA receptor (SNRMs) technology. It is a new ...

GNT Pharma Co. Ltd, a late-stage pharmaceutical company founded in 1998 with offices in Seoul Korea, Italy and USA, announced today the results of its latest Phase II ('SONIC') and Phase III ('Rodin') ...

Apimostinel has a similar mode of action to ketamine and derivatives like Johnson & Johnson's Spravato (esketamine) – ...

Relmada Therapeutics will halt two Phase III trials of a major depressive disorder drug after a futility assessment and ...

Relmada halted Phase 3 trials of NMDA receptor blocker for depression but will continue its early psilocybin program while ...

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS) and metabolic disorders. Relmada’s experienced and dedicated team is committed to ...

If you're struggling to sleep, you've probably tried many methods to doze off more easily – but one doctor has shared a ...

Following the news, shares of Relmada had plunged sharply. REL-1017 is a new chemical entity or NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels ...